Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tian-Ren Zhou

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Asian Journal of Andrology|August 26, 2022
FOXA1 in prostate cancerHui-Yu Dong, Lei Ding, Tian-Ren Zhou, et al.
Asian Journal of Andrology|February 1, 2023
Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsyYu-Hao Wang, Chao Liang, Fei-Peng Zhu, et al.
Asian Journal of Andrology|June 7, 2023
Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathwayHui-Yu Dong, Pan Zang, Mei-Ling Bao, et al.
Cancer Medicine|August 12, 2021
PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapiesLei Ding, Hui Yu Dong, Tian Ren Zhou, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Asian Journal of Andrology|August 26, 2022
FOXA1 in prostate cancerHui-Yu Dong, Lei Ding, Tian-Ren Zhou, et al.
Asian Journal of Andrology|February 1, 2023
Improving the understanding of PI-RADS in practice: characters of PI-RADS 4 and 5 lesions with negative biopsyYu-Hao Wang, Chao Liang, Fei-Peng Zhu, et al.
Asian Journal of Andrology|June 7, 2023
Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathwayHui-Yu Dong, Pan Zang, Mei-Ling Bao, et al.
Cancer Medicine|August 12, 2021
PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapiesLei Ding, Hui Yu Dong, Tian Ren Zhou, et al.
Pageof 1